Skip to main content

Find Clinical Trials

Home
Conditions
Anemia, Refractory

Clinical trial condition

Anemia, Refractory

Explore clinical trials studying Anemia, Refractory. Study availability and eligibility vary by location and protocol.

188 public trials 35 recruiting studies

Refine in advanced search Browse all conditions

Anemia, Refractory trial results

Completed

SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes

NCT00098826

Conditions: Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), +60 more
Locations: Case Western Reserve University Cleveland, Ohio, United States

View Trial Details

Completed

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

NCT00004918

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Anemia, +23 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease

NCT00295971

Conditions: Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +21 more
Locations: UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States

View Trial Details

Completed

Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia

NCT00513175

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adenocarcinoma, +61 more
Locations: University of California San Francisco San Francisco, California, United States

View Trial Details

Completed

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

NCT00296023

Conditions: Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +64 more
Locations: Alta Bates Comprehensive Cancer Center Berkeley, California, United States

UCSF Comprehensive Cancer Center San Francisco, California, United States

View Trial Details

Completed

Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome

NCT00002547

Conditions: Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +21 more
Locations: Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States

View Trial Details

Completed

Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

NCT00004263

Conditions: Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +9 more
Locations: Arthur G. James Cancer Hospital - Ohio State University Columbus, Ohio, United States

University of Texas - MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia

NCT00002833

Conditions: Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +26 more
Locations: University of Texas - MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

A Phase I Trial of ZIO-101 in Hematologic Cancers

NCT00592046

Conditions: Acute Leukemia, Anemia, Anemia, Refractory, +31 more
Locations: Houston, Texas, United States

View Trial Details

Completed

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome

NCT00732316

Conditions: Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +30 more
Locations: Asan Medical Center - University of Ulsan College of Medicine Seoul, South Korea

View Trial Details